Neuroendocrine neoplasia goes molecular — time for a change

Guido Rindi, Bertram Wiedenmann

Research output: Contribution to journalArticle

Abstract

In a cohort of 100 patients with neuroendocrine cancer, the use of NETest enabled earlier prediction of tumour progression and resulted in a reduction in the frequency of follow-up procedures. These outcomes are exciting and promising, but limited in value by the heterogeneity of the study cohort and by suboptimal assay sensitivity and specificity.

Original languageEnglish
JournalNature Reviews Clinical Oncology
DOIs
Publication statusAccepted/In press - Jan 1 2018

    Fingerprint

ASJC Scopus subject areas

  • Oncology

Cite this